Several new gene therapies are launching in the US in an exciting development for the field, but successful commercial execution is not a guarantee with any launch, let alone a challenging area like gene therapy, filled with reimbursement and administration pitfalls.
Investors in the companies launching the latest round of new entrants are closely watching the early uptake of the products, and successful commercialization could also have broader consequences for the field,